Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zangerle

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Current Drug Metabolism|April 14, 2007
Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infectionKatharina Schroecksnadel, R Zangerle, R Bellmann-Weiler, et al.
Clinical Nephrology|November 15, 2000
Pyuria in patients treated with indinavir is associated with renal dysfunctionM Sarcletti, A Petter, N Romani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1994
Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activationR Zangerle, H Gallati, M Sarcletti, et al.
Nuclear Medicine Communications|August 1, 1992
Double-tracer SPECT in patients with AIDS encephalopathy: a comparison of 123I-IMP with 99Tcm-HMPAOP Pohl, G Riccabona, E Hilty, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
Increased interferon-gamma and reduced hemoglobin in patients with human immunodeficiency virus type 1 infectionD Fuchs, R Zangerle, E Artner-Dworzak, et al.
European Journal of Haematology|January 1, 1995
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosisA Diez-Ruiz, G P Tilz, R Zangerle, et al.
International Archives of Allergy and Immunology|August 7, 1998
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individualsR Zangerle, S Steinhuber, M Sarcletti, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 4, 2003
Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIVG Kemmler, B Schmied, A Shetty-Lee, et al.
Journal of Acquired Immune Deficiency Syndromes|March 1, 1993
Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) in HIV-1 infectionJ Möst, R Zangerle, M Herold, et al.
Brain, Behavior, and Immunity|February 12, 2008
Quality of life and immune activation in patients with HIV-infectionK Schroecksnadel, M Sarcletti, C Winkler, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Current Drug Metabolism|April 14, 2007
Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infectionKatharina Schroecksnadel, R Zangerle, R Bellmann-Weiler, et al.
Clinical Nephrology|November 15, 2000
Pyuria in patients treated with indinavir is associated with renal dysfunctionM Sarcletti, A Petter, N Romani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1994
Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activationR Zangerle, H Gallati, M Sarcletti, et al.
Nuclear Medicine Communications|August 1, 1992
Double-tracer SPECT in patients with AIDS encephalopathy: a comparison of 123I-IMP with 99Tcm-HMPAOP Pohl, G Riccabona, E Hilty, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
Increased interferon-gamma and reduced hemoglobin in patients with human immunodeficiency virus type 1 infectionD Fuchs, R Zangerle, E Artner-Dworzak, et al.
European Journal of Haematology|January 1, 1995
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosisA Diez-Ruiz, G P Tilz, R Zangerle, et al.
International Archives of Allergy and Immunology|August 7, 1998
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individualsR Zangerle, S Steinhuber, M Sarcletti, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 4, 2003
Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIVG Kemmler, B Schmied, A Shetty-Lee, et al.
Journal of Acquired Immune Deficiency Syndromes|March 1, 1993
Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) in HIV-1 infectionJ Möst, R Zangerle, M Herold, et al.
Brain, Behavior, and Immunity|February 12, 2008
Quality of life and immune activation in patients with HIV-infectionK Schroecksnadel, M Sarcletti, C Winkler, et al.
Pageof 8